9MW3011

Product Description

9MW3011 is monoclonal antibody with an innovative target. It is independently developed by Innovation R&D Center of Mabwell in San Diego, U.S., belonging to Category 1 Therapeutic Biological Products. With its target mainly expressed on the surfaces of liver cell membranes, 9MW3011 can upregulate the level of hepcidin expressed by hepatocytes through specific binding, inhibit the absorption and release of iron, and lower the serum iron level, thus regulating the iron homeostasis in vivo. (Sourced from: https://mabwell.com/en/news_info/id-91.html)

Mechanisms of Action: Iron Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation:
Fast Track -
Orphan Drug - *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None